Sarepta (SRPT) Soars on FDA Approval on Muscular Dystrophy Treatment

8:52   SRPT Q4 Earnings Breakdown: ELEVIDYS Reset, Profitability in 2026? 6:15   Sarepta Therapeutics ($SRPT): Is $21.71 a Generational Deep Value Opportunity? 7:23   SRPT 2025 Revenue Hits $1.86B — ELEVIDYS Sales Floor $500M in 2026 3:51   TD Cowen's Ritu Bara talks Sarepta stock skyrocketing on FDA gene therapy approval 11:26   SRPT Stock Crash: ESSENCE Trial Miss Explained | Sarepta Q3 2025 Earnings & ELEVIDYS FDA Update 3:18   ArkInvest Spent MILLIONS On Sarepta Therapeutics [SRPT Stock]. I also bought into this company 8:43   FDA's 44-Day Approval | Sarepta CEO Exits | BioMarin Pulls Roctavian 8:36   SRPT Stock CRASHING – Why Sarepta Therapeutics Is Down 11% Today (Regulatory & Revenue Fears) 13:06   Sarepta Therapeutics Stock Analysis – Should I Buy or Sell ? SRPT Stock Analysis 5:37   It's a disaster: SRPT 4:13   The Daily Pulse: Monday June 16, 2025 (SATS, SRPT, SAGE, ROKU, AMD, X) 13:06   SRPT PENN EXEL Top Stocks of the Day! 9:00   Sarepta stock analysis - Massive growth potential 13:18   SRPT Sarepta Therapeutics: 3 Stock Catalysts After JPM - Tuesday Predicted Opening Price? 📈